Healthcare
US Pharmaceutical Manufacturing Market Size, 2024-2033
USD Billion
The figures are in the full report. Request a free sample ↗
Market overview
| Study Period | 2024 - 2033 |
|---|---|
| Historic Year | 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2033 |
| Market Size (Base Year) | USD 280.7 Billion |
| Market Size (Forecast Year) | USD 475.7 Billion |
| Growth Rate (CAGR) | 6.8 % |
| Fastest Growing Market | The South |
| Largest Market | The West |
| Market Concentration | Medium |
Pages from the sample report. Figures are shown as XX here; the full report has them.
See the full sample: Request a free sample ↗
The US pharmaceutical manufacturing market covers medicines made in the United States, including tablets, injectables, biologic drugs, vaccines, active pharmaceutical ingredients, diagnostic reagents and botanical products, whether sold at home or exported.
The market is measured by the value of shipments from US plants at manufacturers' prices. It is growing as drug makers move production of medicines for the US market back to the United States, encouraged by tariffs on imported drugs and concerns about supply security.
Drug makers are building and expanding US plants to make more of the medicines they sell in the United States, in response to tariffs on imported patented drugs and to concerns about relying on supply chains abroad.
Demand for biologic medicines and for injectable obesity and diabetes drugs is rising fast, and much of the new capacity for active ingredients, biologics and fill-finish is being built in the United States.
However, a new plant takes several years to build and qualify, skilled workers are scarce, and pricing agreements with the government may limit what manufacturers earn. Generic medicines, mostly imported, remain cheaper to make abroad.
The US Pharmaceutical Manufacturing market is mainly classified based on product type. By product type, the market covers pharmaceutical preparations, biological products, in-vitro diagnostic substances, and medicinal and botanical products.
Pharmaceutical preparations, such as tablets, capsules and injectable medicines, account for the largest share. Biological products, including antibodies, vaccines and other medicines made from living cells, grow fastest as new biologics plants open.
The West is the largest region, led by California, home to many biotechnology companies and biologics plants. The Northeast and Midwest are long-established centres, with New Jersey, New York, Pennsylvania, Massachusetts and Indiana among the leading states.
The South is the fastest-growing region, as most of the new plants announced since 2024 are in North Carolina, Virginia, Texas, Alabama and Maryland, where land, workers and state incentives are available.
Some of the major competitors in the global US Pharmaceutical Manufacturing market include Eli Lilly and Company, Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals, Inc., Genentech (Roche), Novo Nordisk A/S, AstraZeneca plc, Novartis AG, and FUJIFILM Biotechnologies.
The US Pharmaceutical Manufacturing market is moderately concentrated. Large drug makers with US plants include Eli Lilly, Johnson & Johnson, Pfizer, Merck, AbbVie, Amgen, Regeneron and Genentech (Roche), while Novo Nordisk, AstraZeneca and Novartis are expanding their US production, and contract manufacturers such as FUJIFILM Biotechnologies build capacity for others. Competition turns on manufacturing capacity, speed to build and qualify new plants, cost, and access to skilled workers.
Ans: The US Pharmaceutical Manufacturing market was valued at USD 280.7 billion in 2025 and is projected to reach USD 475.7 billion by 2033, at a CAGR of 6.8% during the forecast period.
Ans: New plants for active ingredients, biologics and injectable obesity medicines, contract manufacturing, and replacing imported medicines are major opportunities.
Ans: Onshoring of drug production, encouraged by tariffs on imported medicines and supply-security concerns, is the main growth driver.
Ans: The West has the largest share, led by California, while the South is growing fastest.
Ans: Pharmaceutical preparations account for the largest share, while biological products grow fastest.
The United States has pushed drug makers to produce more medicines at home. A Section 232 proclamation in April 2026 placed tariffs on imported patented medicines and their active ingredients, with lower rates for countries that have trade deals and exemptions for companies that are building US plants or have signed pricing agreements.
Drug makers have responded with a wave of new US plants and expansions, many of them in North Carolina, Virginia, Indiana, Texas and Pennsylvania, covering active ingredients, biologics, and fill-finish lines for injectable medicines such as obesity drugs.
US imports of medicines have fallen in 2026 while US shipments have risen, as companies make more of what they sell in the United States at home. Generic medicines, most of which are imported, have so far been left out of the tariffs.
New plants take years to build and approve, and pricing agreements may hold down what manufacturers earn. This report counts US production only, follows reported shipments for 2026 and assumes new capacity comes on line in the years companies have announced.
Backed by 1 million+ hours of research experience across the industries we cover.
Domains covered
Countries covered
Committed to timely delivery
Projects delivered